iSpecimen (ISPC)

What Moves the Stock

1. 01New pharmaceutical or biotech partnership announcements expanding buyer network
2. 02Quarterly transaction volume growth and average order value trends
3. 03Cash runway updates and financing announcements given liquidity constraints
4. 04Regulatory developments affecting biospecimen procurement and patient consent requirements
5. 05Competitor marketplace activity or consolidation in fragmented biospecimen industry
6. 06Marketplace transaction fees from biospecimen procurement (estimated 70-80% of revenue)
7. 07Technology platform subscription fees from provider network participants (estimated 15-20%)
8. 08Ancillary services including specimen logistics and quality assurance (estimated 5-10%)

ISPC Chart

My Notes

• Highly speculative momentum traders and distressed/turnaround investors willing to accept binary outcomes.
• Rising interest rates negatively impact iSpecimen through multiple channels: (1) biotech customer funding becomes scarcer as venture capital…
• Watch on earnings: Monthly cash burn rate and total cash balance relative to quarterly operating losses, Biotech venture capital funding volumes (indicator of customer spending capacity), FDA new drug application approvals and clinical trial starts (leading indicators of biospecimen demand).